Tempus operates in precision oncology and multi-disease AI — a total addressable market estimated at $40–70B in oncology alone, expanding to $200B+ when cardiology, mental health, and radiology are included. The runway extends 15–20 years as AI increasingly drives clinical decision-making, pharmaceutical R&D, and population health management. Tempus is not simply the largest player — it is structurally differentiated by the breadth of its multimodal data asset: genomic sequences, pathology images, radiology scans, and EHR data all linked to long-term patient outcomes. No competitor has assembled this combination at this scale.

The data flywheel is the core moat mechanism. Every genomic test ordered through Tempus enriches the underlying dataset. A larger dataset trains more predictive AI models. More predictive models attract more pharmaceutical partnerships for drug discovery and clinical trial matching. More partnerships generate incremental data, closing the loop. The company already works with 95% of the top 20 pharmaceutical oncology companies — evidence that the flywheel has reached meaningful scale. Critically, 7,000+ physicians (representing more than 50% of U.S. oncologists) are connected to the platform, creating a network effect on the clinical side.

The primary ceiling on the monopoly score is the competitive landscape. Roche owns both Foundation Medicine (genomic diagnostics) and Flatiron Health (oncology data platform), creating a well-resourced vertically integrated rival. However, neither Roche nor any single competitor matches the multimodal breadth of Tempus' dataset, and the company's neutral positioning — not owned by a pharma company — is a structural advantage in attracting multiple competing pharmaceutical partners simultaneously.

Trait 1 — Missionary vision (20%) — 8/10
Eric Lefkofsky founded Tempus in 2015 after his wife was diagnosed with breast cancer and he was confronted with the absence of structured clinical data to guide treatment decisions. The mission — to connect every patient's molecular and clinical data to outcomes in real time — is specific, audacious, and directly traceable in every product and capital allocation decision the company makes. The expansion from oncology into cardiology, radiology, and mental health is the logical extension of a conviction that every disease state deserves a data infrastructure.

Trait 2 — Radical long-termism & skin in the game (25%) — 7/10
Lefkofsky holds approximately 27% of the company — one of the largest individual insider positions for a post-IPO health tech company — which creates strong long-term alignment. He has demonstrated willingness to sacrifice near-term profitability to build platform infrastructure, including the Ambry Genetics acquisition ahead of monetisation. The framework concern is $250M+ in insider share sales between December 2024 and February 2025, occurring while the stock was in material decline. The sales are not disqualifying but represent a deviation from the total conviction posture that scores a 9 or 10 on this trait.

Trait 3 — Product & customer obsession (20%) — 8/10
Connecting more than 50% of U.S. oncologists to a single platform is a product achievement. MRD testing volume grew 56% quarter-over-quarter in Q4 2025, suggesting rapid physician adoption of a new product line. The Merck strategic collaboration signed March 2026 validates the Lens Platform and GPU Workspaces as credible enterprise AI products, not just data repositories.

Trait 4 — Execution velocity (20%) — 8/10
83% revenue growth in FY2025 on a $693M base is exceptional execution. Two consecutive positive Adjusted EBITDA quarters (Q3 and Q4 2025) signal that management is converting growth into financial leverage. The 2026 guidance of $1.59B (+25%) with $65M Adjusted EBITDA, if achieved, will mark the company's first fully profitable fiscal year.

Trait 5 — Capital efficiency & financial discipline (10%) — 6/10
The balance sheet carries $1.25B in total debt against $760M cash — a net debt position of $490M — while burning $218M in operating cash annually. The $750M convertible note issuance adds dilution risk. Management has articulated a credible path to FCF positivity by 2026, and EBITDA improvement has been rapid, but the debt structure limits the margin of error if growth disappoints.

Trait 6 — Talent magnetism & organisational scaling (5%) — 7/10
Lefkofsky is a serial founder (Groupon, Echo Global Logistics, InnerWorkings, Mediaocean) with an established network of technology and healthcare talent. The clinical and AI team — managing a diagnostics lab at scale, a data licensing platform, and multiple AI product lines simultaneously — reflects a mature engineering and scientific organisation.

Valuation — ABOVE THRESHOLD
At $42.53, Tempus trades at 6.0x FY2025 revenue — above the framework's preferred entry threshold of 5x. On 2026E revenue of $1.59B, the forward P/S compresses to approximately 4.8x, which sits just inside the threshold if management guidance is met. The 60% decline from the 52-week high of $104.32 represents a meaningful valuation reset from AI hype pricing. The entry trigger for a meaningful position is a drawdown toward $30–35 (P/S of 4.0–4.5x on FY2025 revenue).

Revenue and margin trajectory
The revenue trajectory is exceptional: $693M in FY2024 to $1.27B in FY2025 (+83%), driven by the Ambry integration and organic Data & Services acceleration (+69% in Q4). Gross margin is expanding — reaching 63.6% in Q3 2025 vs. approximately 59% a year prior — driven by better pricing in genomics and growing weight of the higher-margin Data & Services segment. If Data & Services grows to 40%+ of revenue (from 25% today), blended gross margins should reach 70%+.

Balance sheet and path to profitability
With $490M net debt and $218M annual operating cash burn, Tempus has approximately 3.5 years of runway before a capital raise becomes necessary — assuming no FCF improvement. The 2026 FCF guidance of $21M positive is the crucial transition, and two consecutive EBITDA-positive quarters entering 2026 make this credible. This is a balance sheet that supports a WATCHLIST rating, not a BUY, until profitability is confirmed with positive FCF.

Net Debt & Profitability Execution Risk
With $490M net debt and $218M in FY2025 operating cash burn, Tempus is dependent on executing its 2026 profitability pivot. Any meaningful revenue miss could require an equity raise at dilutive terms. The convertible note structure also creates overhang at conversion thresholds.

Roche / Foundation Medicine Vertical Integration
Roche's ownership of both Foundation Medicine and Flatiron Health means Tempus faces a well-capitalised competitor capable of offering an integrated solution to pharmaceutical partners. If Roche aggressively bundles its offerings, Tempus could face pricing pressure in both segments.

Revenue Concentration in Oncology Diagnostics
Approximately 75% of revenue is still derived from genomic diagnostics — a business that carries reimbursement risk from CMS and commercial payers. Any adverse change in coverage determinations would directly impact the largest revenue stream.

Data Privacy & Regulatory Scrutiny
A business model built on aggregating and monetising de-identified patient data is sensitive to evolving state and federal privacy regulations. A high-profile breach or adverse ruling on de-identification standards could structurally impair the data licensing business.

AI Commoditisation Risk
As foundation AI models improve and open-source alternatives proliferate, the marginal value of any single proprietary dataset may compress. Tempus must continuously expand the depth and uniqueness of its data asset to defend against commoditisation.